OS THERAPIES INCORPORATED Increase (Decrease) in Accrued Liabilities
OS THERAPIES INCORPORATED (OSTX) reported Increase (Decrease) in Accrued Liabilities of $8.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-14
- OS THERAPIES INCORPORATED increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $5.01M, a 354.90% increase year-over-year.
- OS THERAPIES INCORPORATED increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $3.88M.
- OS THERAPIES INCORPORATED increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $1.02M, a 353.92% increase year-over-year.
- OS THERAPIES INCORPORATED increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$1.03M, a 1041.70% decline year-over-year.
- OS THERAPIES INCORPORATED increase (decrease) in accrued liabilities for fiscal 2025 was $893.99K, a 149.36% increase from fiscal 2024.
- OS THERAPIES INCORPORATED increase (decrease) in accrued liabilities for fiscal 2024 was $358.51K, a 143.06% increase from fiscal 2023.
- OS THERAPIES INCORPORATED increase (decrease) in accrued liabilities for fiscal 2023 was $147.50K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $8.90M 10-Q · filed 2026-08-14 | $9.92M derived: sum of 3 quarters · filed 2026-08-14 | $8.89M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $3.88M 10-Q · filed 2026-05-18 | $4.90M derived: sum of 2 quarters · filed 2026-05-18 | $3.88M derived: sum of 3 quarters · filed 2026-05-18 | $4.98M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$5.96K derived: sum of 2 quarters · filed 2026-03-31 | $1.10M derived: sum of 3 quarters · filed 2026-08-14 | $893.99K 10-K · filed 2026-03-31 | ||
| 2025-09-30 | -$1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $76.72K derived: sum of 2 quarters · filed 2026-08-14 | -$125.56K 10-Q · filed 2025-11-14 | $99.05K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $899.96K 10-Q · filed 2026-08-14 | -$140.70K 10-Q · filed 2025-08-18 | $1.12M derived: sum of 3 quarters · filed 2026-08-14 | $1.23M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | -$202.28K 10-Q · filed 2026-05-18 | -$156.60K 10-Q · filed 2025-05-15 | $22.33K derived: sum of 2 quarters · filed 2026-05-18 | $131.23K derived: sum of 3 quarters · filed 2026-05-18 | ||
| 2024-12-31 | $224.61K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $333.51K derived: sum of 2 quarters · filed 2026-03-31 | $358.51K 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $108.90K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $133.90K 10-Q · filed 2025-11-14 | ||||
| 2024-06-30 | $25.00K 10-Q · filed 2025-08-18 | |||||
| 2023-12-31 | $162.50K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $162.50K derived: sum of 2 quarters · filed 2025-03-31 | $137.50K derived: sum of 3 quarters · filed 2025-03-31 | $147.50K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | -$25.00K derived: sum of 2 quarters · filed 2024-11-15 | -$15.00K 10-Q · filed 2024-11-15 | |||
| 2023-06-30 | -$25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$15.00K 10-Q · filed 2024-08-14 | ||||
| 2023-03-31 | $10.00K 10-Q · filed 2024-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |